Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03743766
Title Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors John Kirkwood
Indications

melanoma

Therapies

Relatlimab

Nivolumab + Relatlimab

Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.